Inactive Instrument

News NeoStem Inc Nasdaq

Equities

US6406504042

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 23	Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer	MT
Apr. 23	Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	Apr. 24	AQ
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors	Apr. 23	AQ
Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer	Apr. 23	MT
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	Apr. 23	GL
Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	Apr. 23	CI
Lisata Therapeutics, Inc. Appoints James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer	Apr. 17	CI
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	Apr. 09	GL
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	Apr. 09	CI
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events	Apr. 03	GL
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	Mar. 21	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Mar. 21	MT
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug	Mar. 21	MT
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma	Mar. 21	GL
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ	Mar. 04	AQ
Transcript : Lisata Therapeutics, Inc., 2023 Earnings Call, Feb 29, 2024	Feb. 29
Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	Feb. 29	GL
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	Feb. 22	GL
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	Feb. 22	AQ
Lisata Therapeutics to Present at BIO CEO & Investor Conference	Feb. 20	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News NeoStem Inc Nasdaq

Equities

US6406504042

Summary

Filters